TABLE 2.
Summary of the treatment course and outcomes of Australian patients with mesenchymal chondrosarcoma, N = 22
| Case number | Age (years) | Sex | Tumour site at presentation | Treatment for the primary | Metastasis, recurrence (site) | Treatment for metastasis or recurrence/progression | Chemotherapy regimen | Outcome (months) |
|---|---|---|---|---|---|---|---|---|
| Presented without metastasis | ||||||||
| 1 | 10 | F | Vertebra | S | LR | S (×5), R (×2), CT (×1) | D | DOD (183.2) |
| 3 | 25 | M | Pelvis | S, R | LR + MR (bone) | S (×5), R, CT (×3) | IrT, P, VDC/IE | AWD (96.7) |
| 5 | 24 | M | 3rd metatarsal | S | NED (26.7) | |||
| 6 | 26 | M | Maxilla | S, R, CT | LR + MR (lung) | S (×2), R | DI | DOD (211.0) |
| 7 | 28 | F | Maxilla | S (x2) | NED (2.7) | |||
| 8 | 59 | M | Thigh | CT, R | UK | UK | DOD (16.9) | |
| 9 | 18 | F | Missing | CT | UK | DaDI | DOD (7.0) | |
| 10 | 44 | F | Bone (UK) | S, R | NED (30.4) | |||
| 11 | 30 | F | Rib | S | NED (0.4) | |||
| 12 | 20 | M | Distal femur | S | MR (lung) | S (×5), R (×3), CT (×6) | M, DIV, DaDIV, VDaCE, trialx2 a , UK | DOD (101.9) |
| 13 | 33 | F | Rib | S | MR (bone) | S, R (×4), CT | VDC/IE | DOD (26.1) |
| 14 | 22 | F | Rib | S, R | NED (21.4) | |||
| 15 | 39 | M | Vertebra | S | NED (0.0) | |||
| 16 | 48 | F | Vertebra | R, S | LR + MR (bone) | S, R | AWD (119.2) | |
| 17 | 14 | F | Quadriceps | S | NED (59.1) | |||
| 18 | 37 | M | Buttock | S, R | LR + MR (lung) | S (×3), R (×2) | DOD (90.3) | |
| 29 | 38 | M | Bone (UK) | CT, S | MR (bone) | CT (×2) | DzDI, trial | DOD (8.9) |
| 21 | 11 | M | Lower leg | S, CT | VDC/IE | NED (13.8) | ||
| 22 | 36 | F | Spine | CT, R | VDC/IE | AWD (9.4) | ||
| Presented with metastasis | ||||||||
| 2 | 32 | F | Calf (lung) | CT, S | n/a | S (×2), R (×6), CT (×4) | VIDE, VDC, trial b , GDo, E | DOD (34.9) |
| 4 | 28 | M | Pelvis (lung) | CT, R | n/a | R, CT (×4) | VIDE, VDaC, trial b , trial c , GDo | AWD (34.9) |
| 20 | 27 | F | Pelvis/sacrum (lung, node) | CT, R | n/a | VDC/IE | AWD (15.7) | |
Abbreviations: AWD, alive with disease; C, cyclophosphamide; CT, chemotherapy; D, doxorubicin; Da, dactinomycin; Do, docetaxel; DOD, dead of disease; Dz, dacarbazine; E, etoposide; G, gemcitabine; I, ifosfamide; Ir, irinotecan; LR, local recurrence; M, methotrexate; NED, no evidence of disease; R, radiation; S, surgery; UK, unknown; MR, metastatic recurrence; P, pazopanib; T, temozolamide; V, vincristine.
a
Investigational targeted agent.
b
Immunotherapy trial.
c
RAF inhibitor.